| Product name: |
Tafazzin rabbit pAb |
| Reactivity: |
Human;Rat;Mouse; |
| Alternative Names: |
TAZ; EFE2; G4.5; Tafazzin; Protein G4.5 |
| Source: |
Rabbit |
| Dilutions: |
Western Blot: 1/500 – 1/2000. ELISA: 1/5000. Not yet tested in other applications. |
| Immunogen: |
Synthesized peptide derived from the Internal region of human Tafazzin. |
| Storage: |
-20C/1 year |
| Clonality: |
Polyclonal |
| Isotype: |
IgG |
| Concentration: |
1 mg/ml |
| Observed Band: |
33kD |
| GeneID: |
6901 |
| Human Swiss-Prot No: |
Q16635 |
| Cellular localization: |
Mitochondrion outer membrane ; Peripheral membrane protein ; Intermembrane side . Mitochondrion inner membrane ; Peripheral membrane protein ; Intermembrane side .; [Isoform 1]: Mitochondrion membrane .; [Isoform 2]: Cytoplasm .; [Isoform 3]: Mitochondrion membrane .; [Isoform 5]: Mitochondrion membrane .; [Isoform 6]: Cytoplasm .; [Isoform 7]: Mitochondrion membrane .; [Isoform 8]: Cytoplasm .; [Isoform 9]: Cytoplasm . |
| Background: |
This gene encodes a protein that is expressed at high levels in cardiac and skeletal muscle. Mutations in this gene have been associated with a number of clinical disorders including Barth syndrome, dilated cardiomyopathy (DCM), hypertrophic DCM, endocardial fibroelastosis, and left ventricular noncompaction (LVNC). Multiple transcript variants encoding different isoforms have been described. A long form and a short form of each of these isoforms is produced; the short form lacks a hydrophobic leader sequence and may exist as a cytoplasmic protein rather than being membrane-bound. Other alternatively spliced transcripts have been described but the full-length nature of all these transcripts is not known. [provided by RefSeq, Jul 2008], |
